Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: Recommendations from the International Collaboration on Cancer Reporting (ICCR)

Modern Pathology

Volumn 28, Issue 8, 2015, Pages 1101-1122

  Glenn Mccluggage, W ^a   Judge, Meagan J ^b   Clarke, Blaise A ^c   Davidson, Ben ^d,e   Gilks, C Blake ^f   Hollema, Harry ^g   Ledermann, Jonathan A ^h   Matias Guiu, Xavier ⁱ   Mikami, Yoshiki ^j   Stewart, Colin J R ^k,l   Vang, Russell ^m   Hirschowitz, Lynn ⁿ  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b Royal College of Pathologists of Australasia   (Australia)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^j KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^k KING EDWARD MEMORIAL HOSPITAL   (Australia)

^l UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASCITES; ASCITES FLUID CYTOLOGY; AUSTRALIA AND NEW ZEALAND; CANADA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; DATA BASE; EUROPE; EVIDENCE BASED PRACTICE; FEMALE; FEMALE GENITAL TRACT CANCER; GENE MUTATION; GYNECOLOGIST; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MEDICAL DOCUMENTATION; MEDICAL SOCIETY; OBSTETRICIAN; OVARY CARCINOMA; PARAAORTIC LYMPH NODE; PATHOLOGIST; PERITONEUM CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; TREATMENT RESPONSE; UNITED KINGDOM; UNITED STATES; UTERINE TUBE CARCINOMA; WORLD HEALTH ORGANIZATION; ADJUVANT CHEMOTHERAPY; BIOPSY; CANCER GRADING; CARCINOMA; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; FALLOPIAN TUBE NEOPLASMS; GENETICS; METHODOLOGY; MOLECULAR DIAGNOSIS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS; PRACTICE GUIDELINE; PREDICTIVE VALUE; STANDARDS;

TUMOR MARKER;

BIOMARKERS, TUMOR; BIOPSY; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DIAGNOSIS, DIFFERENTIAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; PATHOLOGY, CLINICAL; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN;

EID: 84938419985     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.77     Document Type: Review

References (164)

1. Kench J, Delahunt B, Griffiths DF et al. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: recommendations from the International Collaboration on Cancer Reporting. Histopathology 2013;62:203-218.
2. McCluggage WG, Colgan T, Duggan M et al. Data Set for Reporting of Endometrial Carcinomas: Recommendations From the International Collaboration on Cancer Reporting (ICCR) Between United Kingdom, United States, Canada, and Australasia. Int J Gynecol Pathol 2012;32:45-65.
3. Scolyer RA, Judge MJ, Evans A et al. Data set for pathology reporting of cutaneous invasive melanoma recommendations from the International Collaboration on Cancer Reporting (ICCR). Am J Surg Pathol 2013;37:1797-1814.
4. Jones KD, Churg A, Henderson DW et al. Data set for reporting of lung carcinomas: recommendations from International Collaboration on Cancer Reporting. Arch Pathol Lab Med 2013;137:1054-1062.
5. Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124: 1-5.
6. Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: revising the Australian 'levels of evidence'. BMC Med Res Methodol 2009;9:34.
7. Suh DH, Kim JW, Kim K et al. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol 2013;24:66-82.
8. Kim HS, Ahn JH, Chung HH et al. Impact of intraopera-tive rupture of the ovarian capsule on prognosis in patients with early-stage epithelial ovarian cancer: a meta-analysis. Eur J Surg Oncol 2013;39:279-289.
9. Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176-182.
10. Bakkum-Gamez JN, Richardson DL, Seamon LG et al. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol 2009;113:11-17.
11. Seidman JD, Yemelyanova AV, Khedmati F et al. Prognostic factors for stage I ovarian carcinoma. Int J Gynecol Pathol 2010;29:1-7.
12. Dembo AJ, Davy M, Stenwig AE et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75:263-273.
13. Ahmed FY, Wiltshaw E, A'Hern RP et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996;14:2968-2975.
14. Timmers PJ, Zwinderman AH, Teodorovic I et al. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. Int J Gynecol Cancer 2009;19: 88-93.
15. Higashi M, Kajiyama H, Shibata K et al. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types. Gynecol Oncol 2011;123:474-478.
16. Gottheil S, McGee J. Endometrioid ovarian carcinoma during pregnancy presenting with acute rupture. J Obstet Gynaecol Can 2013;35:1020-1022.
17. Colgan TJ, Murphy J, Cole DE et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-1289.
18. Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-456.
19. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007;31:161-169.
20. Kuhn E, Meeker A, Wang TL et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcino-genesis. Am J Surg Pathol 2010;34:829-836.
21. Kuhn E, Bahadirli-Talbot A, Kurman R et al. CCNE1 amplification may precede centrosome number abnormality in progression from serous tubal intrae-pithelial carcinoma to high-grade serous carcinoma. Mod Pathol 2013;26:283A.
22. Garg K, Rabban J. Practical value of systematic and complete examination of fallopian tubes in unse-lected women undergoing salpingectomy for benign indications: results of a prospective study. Mod Pathol 2013;26:276A.
23. Przybycin CG, Kurman RJ, Ronnett BM et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-1416.
24. Singh N, Gilks CB, Wilkinson N et al. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology 2014;65:149-154.
25. Wethington SL, Park KJ, Soslow RA et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer 2013;23: 1603-1611.
26. Bloss JD, Liao S, Buller RE et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarci-noma of the ovary. Gynecol Oncol 1993;50:347-351.
27. Doig T, Monaghan H. Sampling the omentum in ovarian neoplasia: when one block is enough. Int J Gynecol Cancer 2006;16:36-40.
28. Usubütün A, Ozseker HS, Himmetoglu C et al. Omentectomy for gynecologic cancer: how much sampling is adequate for microscopic examination? Arch Pathol Lab Med 2007;131:1578-1581.
29. Seidman JD, Soslow RA, Vang R et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol 2004;35:918-933.
30. Kurman RJ, Carcangiu ML, Herrington CS et al. WHO Classification of Tumours of the Female Reproductive Organs. IARC Press: Lyon, France, 2014.
31. McCluggage WG. My approach to and thoughts on typing of ovarian carcinomas. J Clin Pathol 2008;61: 152-163.
32. Shih IM, Kurman RJ. Ovarian tumorigenesis. A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164: 1511-1518.
33. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004;23:200-205.
34. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27:161-174.
35. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 2002;55:321-325.
36. Downes MR, Allo G, McCluggage WG et al. Review of findings in prophylactic gynaecologic specimens in Lynch syndrome with literature review and recommendations for grossing. Histopathology 2014; 65:228-239.
37. Seidman JD, Horkayne-Szakaly I, Haiba M et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004;23:41-44.
38. Köbel M, Kalloger SE, Huntsman DG et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol 2010;29:203-211.
39. Chan JK, Tian C, Monk BJ et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008;112: 2202-2210.
40. Shimizu Y, Kamoi S, Amada S et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 1998;82:893-901.
41. Seidman JD, Horkayne-Szakaly I, Cosin JA et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol 2006;103:703-708.
42. Malpica A, Deavers MT, Lu K et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004;28:496-504.
43. Bodurka DC, Deavers MT, Tian C et al. Reclassifica-tion of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 2012; 118:3087-3094.
44. Yamamoto S, Kasajima A, Takano M et al. Validation of the histologic grading for ovarian clear cell adeno-carcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. Int J Gynecol Pathol 2011;30:129-138.
45. Zaino RJ, Kurgan RJ, Diana KL et al. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading system. A Gynecologic Oncology Group Study. Cancer 1995;75:81-86.
46. Taylor RR, Zeller J, Lieberman RW et al. An analysis of two versus three grades for endometrial carcinoma. Gynecol Oncol 1999;92:119-123.
47. Takeshima N, Hirai Y, Hasumi K. Prognostic validity of neoplastic cells with notable nuclear atypia in endometrial cancer. Obstet Gynecol 1998;92: 119-123.
48. Lax SF, Kurgan RJ, Pizer ES et al. A binary architectural grading system for uterine endometrial endo-metrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000;24:1201-1208.
49. Scholten AN, Smit VT, Beerman H et al. Prognostic significance and interobserver variability of histologic grading system for endometrial carcinoma. Cancer 2004;100:764-772.
50. Alkushi A, Abdul-Rahman ZH, Lim P et al. Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 2005;29:295-304.
51. Bell DA, Longacre TA, Prat J et al. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 2004;35:934-948.
52. Seidman JD, Bell DA, Crum CP et al. Tumours of the ovary: epithelial tumours-serous tumours. In: Kurman RJ, Carcangiu ML, Herrington S et al. (eds). World Health Organization Classification of Tumours of Female Reproductive Organs, 4th (edn). IARC: Lyon, France, 2014.
53. Ellenson LH, Carinelli SG, Cho KR et al. Tumours of the ovary: epithelial tumours-endometrioid and endometrioid stromal tumours. In: Kurman RJ, Carcangiu ML, Herrington S et al. (eds). World Health Organization Classification of Tumours of Female Reproductive Organs, 4th (edn). IARC Press: Lyon, France, 2014.
54. Gilks CB, Bell DA, Huntsman D et al. Tumours of the ovary: epithelial tumours-clear cell tumours. In: Kurman RJ, Carcangiu ML, Herrington S et al. (eds). World Health Organization Classification of Tumours of Female Reproductive Organs, 4th (edn). IARC Press: Lyon, France, 2014.
55. Gilks CB, Carinelli SG, Lawrence WD et al. Tumours of the ovary: epithelial tumours-Brenner tumours. In: Kurman RJ, Carcangiu ML, Herrington S et al. (eds). World Health Organization Classification of Tumours of Female Reproductive Organs, 4th (edn). IARC Press: Lyon, France, 2014.
56. Köbel M, Bell DA, Carcangiu ML et al. Tumours of the ovary: epithelial tumours-seromucinous tumours. In: Kurman RJ, Carcangiu ML, Herrington S et al. (eds). World Health Organization Classification of Tumours of Female Reproductive Organs, 4th (edn). IARC Press: Lyon, France, 2014.
57. Longacre T, Bell D, Malpica A et al. Tumours of the ovary: epithelial tumours-mucinous tumours. In: Kurman RJ, Carcangiu ML, Herrington S et al. (eds). World Health Organization Classification of Tumours of Female Reproductive Organs, 4th (edn). IARC Press: Lyon, France, 2014.
58. Ronnett BM, Kajdacsy-Balla A, Gilks CB et al. Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. Hum Pathol 2004;35:949-960.
59. McKenney JK, Balzer BL, Longacre TA. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevalua-tion of the concept of stromal microinvasion. Am J Surg Pathol 2006;30:1209-1221.
60. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer 1988;62:2212-2222.
61. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol 2001;25:419-432.
62. Longacre TA, McKenney JK, Tazelaar HD et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (4 or = 5-year) follow-up. Am J Surg Pathol 2005;29:707-723.
63. Ardighieri L, Zeppernick F, Hannibal CG et al. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. J Pathol 2014;232: 16-22.
64. Carlson JW, Jarboe EA, Kindelberger D et al. Serous tubal intraepithelial carcinoma: diagnostic reprodu-cibility and its implications. Int J Gynecol Pathol 2010;29:310-314.
65. Visvanathan K, Vang R, Shaw P et al. Diagnosis of serous tubal intraepithelial carcinoma (STIC) based on morphologic and immunohistochemical features. A reproducibility study. Am J Surg Pathol 2011;35: 1766-1775.
66. Vang R, Visvanathan K, Gross A et al. Validation of an algorithm for the diagnosis of serous tubal intra-epithelial carcinoma. Int J Gynecol Pathol 2012;31: 243-253.
67. Tang S, Onuma K, Deb P et al. Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. Int J Gynecol Pathol 2012;31:103-110.
68. Jarboe EA, Miron A, Carlson JW et al. Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance. Int J Gynecol Pathology 2009;28:308-315.
69. Rabban JT, Vohra P, Zaloudek C. Intramucosal growth in fallopian tube fimbriae by tumors of non-gynecologic origin may mimic serous tubal intra-epithelial carcinoma and tubal mucinous metaplasia. Mod Pathol 2014;27:302A.
70. McCluggage WG. WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract. Int J Gynecol Pathol 2004;23:97-99.
71. Berek JS. Lymph node-positive stage IIIC ovarian cancer. A separate entity? Int J Gynecol Cancer 2009;19:S18-S20.
72. Bakker R, Gershenson D, Fox P et al. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogenous group of patients with different prognosis. Int J Gynecol Cancer 2014;33:302-308.
73. Fadare O. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). Int J Gynecol Cancer 2009;19: 103-108.
74. Morice P, Uzan C, Fauvet R et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol 2012;13:e103-e115.
75. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol 2006;30:614-624.
76. Djordjevic B, Malpica A. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma. Am J Surg Pathol 2012;36:955-963.
77. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009;374:1371-1382.
78. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
79. Folkins AK, Longacre TA. Hereditary gynaecological malignancies: advances in screening and treatment. Histopathology 2013;62:2-30.
80. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012;26:2654-2663.
81. Soslow RA, Han G, Park KJ et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012;25: 625-636.
82. Fujiwara M, McGuire VA, Felberg A et al. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria. Identification of a BRCA1 ovarian cancer phenotype. Am J Surg Pathol 2012;36:1170-1177.
83. Dean E, El-Helw L, Hasan J. Targeted therapies in epithelial ovarian cancer. Cancers 2010;2:88-113.
84. Chui MH, Gilks B, Cooper K et al. Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor type. Adv Anat Pathol 2013;20:378-386.
85. Singh N. Synchronous tumours of the female genital tract. Histopathology 2010;56:277-285.
86. Garg K, Soslow RA. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 2009;62:679-684.
87. Miettinen M. Overview of soft tissue tumors. In: Miettinen M(ed). Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions. Cambridge University Press: New York, NY, USA, 2010, pp 1-10.
88. Gramlich T, Austin RM, Lutz M. Histologic sampling requirements in ovarian carcinoma: a review of 51 tumors. Gynecol Oncol 1990;38:249-256.
89. Silverberg SG, Bell DA, Kurman RJ et al. Borderline ovarian tumors: key points and workshop summary. Hum Pathol 2004;35:910-917.
90. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol 2003;27:985-993.
91. Khunamornpong S, Suprasert P, Pojchamarnwiputh S et al. Primary and metastatic mucinous adenocarci-nomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol 2006;101:152-157.
92. Rodríguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol 2002;26:139-152.
93. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma perito-nei'. Am J Surg Pathol 2000;24:1447-6.
94. Nomura K, Aizawa S. Noninvasive, microinvasive, and invasive mucinous carcinomas of the ovary: a clinicopathologic analysis of 40 cases. Cancer 2000;89:1541-1546.
95. Chen S, Leitao MM, Tornos C et al. Invasion patterns in stage I endometrioid and mucinous ovarian carcinomas: a clinicopathologic analysis emphasizing favorable outcomes in carcinomas without destructive stromal invasion and the occasional malignant course of carcinomas with limited destructive stromal invasion. Mod Pathol 2005;18:903-911.
96. Ludwick C, Gilks CB, Miller D et al. Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int J Gynecol Pathol 2005;24:205-217.
97. Tabrizi AD, Kalloger SE, Köbel M et al. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol 2010;29:99-10.
98. Ariyoshi K, Kawauchi S, Kaku T et al. Prognostic factors in ovarian carcinosarcoma: a clinicopatholo-gical and immunohistochemical analysis of 23 cases. Histopathology 2000;37:427-436.
99. Rutledge TL, Gold MA, McMeekin DS et al. Carcino-sarcoma of the ovary-a case series. Gynecol Oncol 2006;100:128-132.
100. Lu CH, Chen IH, Chen YJ et al. Primary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group Study. Int J Gynecol Cancer 2014;24:506-512.
101. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16: 2672-2685.
102. Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-8696.
103. Ruo L, Tickoo S, Klimstra DS et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002;236:75-81.
104. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
105. Gavioli M, Luppi G, Losi L et al. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum 2005;48:1851-1857.
106. Ogston KN, Miller ID, Payne S et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12:320-327.
107. Sataloff DM, Mason BA, Prestipino AJ et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297-306.
108. Corben AD, Abi-Raad R, Popa I et al. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application. Arch Pathol Lab Med 2013;137: 1074-1082.
109. Mandard AM, Dalibard F, Mandard JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinico-pathologic correlation. Cancer 1994;73:2680-2686.
110. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radio-chemotherapy. Int J Colorectal Dis 1997;12:19-23.
111. Chetty R, Gill P, Govender D et al. International study group on rectal cancer regression grading: interobser-ver variability with commonly used regression grading systems. Hum Pathol 2012;43:1917-1923.
112. Chetty R, Gill P, Bateman AC et al. Pathological grading of regression: an International Study Group perspective. J Clin Pathol 2012;65:865-866.
113. Chetty R, Gill P, Govender D et al. A multi-centre pathologist survey on pathological processing and regression grading of colorectal cancer resection specimens treated by neoadjuvant chemoradiation. Virchows Arch 2012;460:151-155.
114. Thies S, Langer R. Tumor Regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol 2013;3:262.
115. Le T, Williams K, Senterman M et al. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulk-ing. Gynecol Oncol 2007;106:160-163.
116. Muraji M, Sudo T, Iwasaki S et al. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. Gynecol Oncol 2013;131:531-534.
117. Petrillo M, Zannoni GF, Tortorella L et al. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol 2014;211, 632 e1-e8.
118. Sassen S, Schmalfeldt B, Avril N et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 2007;38:926-934.
119. Boehm S, Said I, Faruqi A et al. Development of a response scoring system to quantify the effect of neoadjuvant chemotherapy in ovarian cancer-ovarian cancer response scoring (OCRS) study. Mod Pathol 2014;27:276A.
120. McCluggage WG. Recent advances in immunohisto-chemistry in the diagnosis of ovarian neoplasms. J Clin Pathol 2000;53:558-560.
121. McCluggage WG. Recent advances in immunohisto-chemistry in gynaecological pathology. Histopathol-ogy 2002;46:309-326.
122. McCluggage WG, Young RH. Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol 2005;22:3-32.
123. Shimizu M, Toki T, Takagi Y et al. Immunohisto-chemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-163.
124. Al-Hussaini M, Stockman A, Foster H et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology 2004;44:109-115.
125. Goldstein NS, Uzieblo A. WTI immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002; 117:541-545.
126. Acs G, Pasha T, Zhang PJ. WT1 is expressed in serous, but not in endometrioid, clear cell or mucinous carcinoma of the peritoneum, fallopian tube, ovaries and endometrium. Int J Gynecol Pathol 2004;23:110-118.
127. Hashi A, Yuminamochi T, Murata S et al. Wilms' tumor gene immunoreactivity in primary serous carcinomas of the fallopian tube, ovary, endometrium, and peritoneum. Int J Gynecol Pathol 2003;22:374-377.
128. Stewart CJ, Brennan BA, Chan T et al. WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis. Pathology 2008;40: 592-599.
129. O'Neill CJ, McBride HA, Connolly LE et al. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007;50: 773-779.
130. DeLair D, Oliva E, Koble M et al. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol 2011;35:36-44.
131. Yamashita Y, Nagasaka T, Naiki-Ito A et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol 2015;28:111-117.
132. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005;47:231-247.
133. Vang R, Gown AM, Barry TS et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol 2006;30:1130-1139.
134. Ji H, Isacson C, Seidman JD et al. Cytokeratins 7 and 20, Dpc4 and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous carcinomas: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol 2002;21:391-400.
135. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008;32:1566-1571.
136. Tornos C, Soslow R, Chen S et al. Expression of WT1, CA125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005;29:1482-1489.
137. Liu H, Shi J, Wilkerson ML et al. Immunohistochem-ical evaluation of GATA3 expression in tumors and normal tissues: a useful immunomarker for breast and urothelial carcinomas. Am J Clin Pathol 2012;138: 57-64.
138. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127: 103-113.
139. Ronnett BM, Yemelyanova AV, Vang R et al. Endo-cervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 2008;32:1835-1853.
140. McCluggage WG, Young RH. Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseu-doendometrioid sertoli-leydig cell tumors). Am J Surg Pathol 2007;31:592-597.
141. Zhao C, Barner R, Vinh TN et al. SF-1 is a diag-nostically useful immunohistochemical marker and comparable to other sex cord-stromal tumor markers for the differential diagnosis of ovarian Sertoli cell tumor. Int J Gynecol Pathol 2008;27:507-514.
142. Zhao C, Vinh TN, McManus K et al. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol 2009;33:354-366.
143. Vang R, Shih IM, Kurman RJ. Fallopian tube precursors of ovarian low-and high-grade serous neoplasms. Histopathology 2013;62:44-58.
144. McCluggage WG, Connolly LE, McGregor G et al. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int J Gynecol Pathol 2005;24:307-312.
145. Kobel M, Reuss A, Du Bois A et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 2010;222:191-198.
146. McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology 2011;59:786-788.
147. Zaino R, Whitney C, Brady MF et al. Simultaneously detected endometrial and ovarian carcinoma: a prospective clinicopathologic study of 74 cases: a Gynecologic Oncology Group Study. Gynecol Oncol 2001;83:355-362.
148. Ayhan A, Yalcin OT, Tuncer ZS et al. Synchronous primary malignancies of the female genital tract. Eur J Obstet Gynecol Reprod Biol 1992;45:63-66.
149. Hirschowitz L, Ganesan R, McCluggage WG. WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histopathology 2009;55:478-482.
150. Oparka R, McCluggage WG, Herrington CS. Peritoneal mesothelial hyperplasia associated with gynaecological disease: a potential diagnostic pitfall that is commonly associated with endometriosis. J Clin Pathol 2011;64:313-318.
151. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopatho-logical features. Virchows Arch 2012;460:237-249.
152. Kurman RJ, Shih I-M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-443.
153. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
154. Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol 2010;2010:740968.
155. Maeda D, Shih I-M. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 2013;20:45-52.
156. Cuatrecasas M, Villanueva A, Matias-Guiu X et al. K-ras mutations in mucinous ovarian tumors. Cancer 1997;79:1581-1586.
157. Matias-Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology 2013;62: 111-123.
158. Matsuo K, Sheridan TB, Yoshino K et al. Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med 2012;1:156-164.
159. Matsuo K, Yoshino K, Hiramatsu K et al. Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer. Obstet Gynecol 2014;123: 957-965.
160. Qian X, Xi X, Jin Y. The grading of lymphovascular space invasion in epithelial ovarian carcinoma. Int J Gynecol Cancer 2010;20:895-899.
161. Alvarado-Cabrero I, Stolnicu S, Kiyokawa T et al. Carcinoma of the fallopian tube: results of a multi-institutional retrospective analysis of 127 patients with evaluation of staging and prognostic factors. Ann Diagn Pathol 2013;17:159-164.
162. Alvarado-Cabrero I, Young RH, Vamvakas EC et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol 1999;72:367-379.
163. Asmussen M, Kaern J, Kjoerstad K et al. Primary adenocarcinoma localized to the fallopian tubes: report on 33 cases. Gynecol Oncol 1988;30:183-186.
164. Baekelandt M, Jorunn Nesbakken A, Kristensen GB et al. Carcinoma of the fallopian tube. Cancer 2000;89: 2076-2084.